Zalicus Inc Com (NASDAQ:ZLCS)
CAPS Rating:
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
Recs
Bargain price for a stock with HUGE potential. 1000 shares for less than a $1000 mitigates risk.